The possible favorable effects of chymase inhibition after MI from animal experiments were reported as early as 2001,28, 29, 30, 31 and, based on these accumulated data, a clinical phase II trial (ClinicalTrials.gov: NCT02976467) aimed at confirming the effects of a chymase inhibitor on cardiac function in patients with acute MI is now ongoing in Europe. This evidence concerns the gene CMA1 and myocardial infarction.